Viatris Q4 FY25: where the revenue came from and where it went
The income statement of Viatris for this quarter, down to the operating result, as one diagram: what earned the revenue and what it went on. The bottom line is withheld; the note under the table says why.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 26, 2026
Revenue$3.70B
+5% year over year
Gross profit$1.15B
31% margin
Operating profit−$0.19B
−5% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.70 | 100% | +5% |
| Brands | 2.35 | 63% | +8% |
| Other revenue | 0.43 | 12% | |
| Lipitor | 0.38 | 10% | +6% |
| Norvasc | 0.18 | 5% | +5% |
| Lyrica | 0.12 | 3% | −6% |
| Viagra | 0.10 | 3% | +18% |
| Epi pen auto injectors | 0.08 | 2% | +8% |
| Yupelri | 0.07 | 2% | +6% |
| Cost of revenue | −2.56 | 69% | |
| Gross profit | 1.15 | 31% margin | −3pp |
| SG&A | −1.03 | 28% | −2pp |
| Other | −0.31 | 8% | +0pp |
| Operating profit | −0.19 | −5% margin | +0pp |
95 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest